426 related articles for article (PubMed ID: 25165106)
1. Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope.
Upadhyay C; Mayr LM; Zhang J; Kumar R; Gorny MK; Nádas A; Zolla-Pazner S; Hioe CE
J Virol; 2014 Nov; 88(21):12853-65. PubMed ID: 25165106
[TBL] [Abstract][Full Text] [Related]
2. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.
Shen G; Upadhyay C; Zhang J; Pan R; Zolla-Pazner S; Kong XP; Hioe CE
PLoS One; 2015; 10(10):e0141233. PubMed ID: 26491873
[TBL] [Abstract][Full Text] [Related]
3. Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.
Powell RLR; Totrov M; Itri V; Liu X; Fox A; Zolla-Pazner S
J Virol; 2017 Sep; 91(17):. PubMed ID: 28615206
[TBL] [Abstract][Full Text] [Related]
4. Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines.
Hioe CE; Kumar R; Upadhyay C; Jan M; Fox A; Itri V; Peachman KK; Rao M; Liu L; Lo NC; Tuen M; Jiang X; Kong XP; Zolla-Pazner S
Front Immunol; 2018; 9():2441. PubMed ID: 30416503
[TBL] [Abstract][Full Text] [Related]
5. Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL.
Kumar R; Pan R; Upadhyay C; Mayr L; Cohen S; Wang XH; Balasubramanian P; Nádas A; Seaman MS; Zolla-Pazner S; Gorny MK; Kong XP; Hioe CE
J Virol; 2015 Sep; 89(17):9090-102. PubMed ID: 26109728
[TBL] [Abstract][Full Text] [Related]
6. Quantitative assessment of masking of neutralization epitopes in HIV-1.
Agarwal A; Hioe CE; Swetnam J; Zolla-Pazner S; Cardozo T
Vaccine; 2011 Sep; 29(39):6736-41. PubMed ID: 21216319
[TBL] [Abstract][Full Text] [Related]
7. Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells.
Rao PG; Lambert GS; Upadhyay C
J Virol; 2023 Sep; 97(9):e0071023. PubMed ID: 37681958
[TBL] [Abstract][Full Text] [Related]
8. Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.
Kumar R; Tuen M; Liu J; Nàdas A; Pan R; Kong X; Hioe CE
Vaccine; 2013 Nov; 31(46):5413-21. PubMed ID: 24051158
[TBL] [Abstract][Full Text] [Related]
9. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
[TBL] [Abstract][Full Text] [Related]
10. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
[TBL] [Abstract][Full Text] [Related]
11. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
12. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.
Kong R; Louder MK; Wagh K; Bailer RT; deCamp A; Greene K; Gao H; Taft JD; Gazumyan A; Liu C; Nussenzweig MC; Korber B; Montefiori DC; Mascola JR
J Virol; 2015 Mar; 89(5):2659-71. PubMed ID: 25520506
[TBL] [Abstract][Full Text] [Related]
13. Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.
Andrabi R; Kumar R; Bala M; Nair A; Biswas A; Wig N; Kumar P; Pal R; Sinha S; Luthra K
Virol J; 2012 Sep; 9():196. PubMed ID: 22971578
[TBL] [Abstract][Full Text] [Related]
14. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
Gorny MK; Williams C; Volsky B; Revesz K; Cohen S; Polonis VR; Honnen WJ; Kayman SC; Krachmarov C; Pinter A; Zolla-Pazner S
J Virol; 2002 Sep; 76(18):9035-45. PubMed ID: 12186887
[TBL] [Abstract][Full Text] [Related]
15. Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.
Peachman KK; Karasavvas N; Chenine AL; McLinden R; Rerks-Ngarm S; Jaranit K; Nitayaphan S; Pitisuttithum P; Tovanabutra S; Zolla-Pazner S; Michael NL; Kim JH; Alving CR; Rao M
PLoS One; 2015; 10(12):e0143895. PubMed ID: 26625359
[TBL] [Abstract][Full Text] [Related]
16. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
17. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
[TBL] [Abstract][Full Text] [Related]
18. Antibody Recognition of CD4-Induced Open HIV-1 Env Trimers.
Yang Z; Dam KA; Gershoni JM; Zolla-Pazner S; Bjorkman PJ
J Virol; 2022 Dec; 96(24):e0108222. PubMed ID: 36448805
[TBL] [Abstract][Full Text] [Related]
19. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
20. Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.
Zolla-Pazner S; Cohen SS; Boyd D; Kong XP; Seaman M; Nussenzweig M; Klein F; Overbaugh J; Totrov M
J Virol; 2016 Jan; 90(2):636-49. PubMed ID: 26491157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
